Equity Profile

TYRA

Tyra Biosciences, Inc.

Health CareBiotechnology$1.6B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors will closely analyze.

N/A

Revenue Growth

Although revenue estimates are not available, any growth in revenue would signal positive momentum for the company.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TYRA Q2-2026 Earnings Preview

Context

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. With a market cap of $2 billion, it operates in the health care sector, which is increasingly important as advancements in biotechnology continue to shape patient care and treatment options.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.57%

Avg Stock Reaction

+0.14%

Last Quarter Recap

In Q1-2026, Tyra reported an EPS of -$0.64, missing estimates slightly. The stock reacted positively, gaining 3.79% the next day, indicating some investor optimism despite the loss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has shown both positive and negative surprises in the past. Investors are keen to see if Tyra can turn around its recent performance and deliver better results this quarter.

Bull Case

If Tyra can demonstrate significant progress in its clinical trials or report better-than-expected EPS, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company fails to meet expectations again or provides disappointing updates on its therapies, it could lead to a further decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of clinical trials?

Investors will be looking for any signs of success or setbacks in the trials, as these can greatly influence the stock's future performance.

How does management plan to address the recent EPS misses?

Understanding management's strategy to improve financial performance is crucial for investor confidence and stock stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Tyra's upcoming clinical trial results, which could be more favorable than anticipated.

Supporting Evidence

The options market is pricing a 9.39% move, suggesting significant expectations that may not align with historical performance.

Tyra's recent stock reactions indicate a potential for recovery if positive news emerges from clinical trials.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it could set the tone for Tyra's future growth and investor sentiment.

Bull Confirmed If

A significant improvement in clinical trial results or a surprise EPS beat could confirm the bull case.

Bear Confirmed If

Continued EPS misses or negative updates on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.39%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, indicating that investors are anticipating volatility around the earnings report.

Options are pricing ±9.4% while TYRA has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

47.9%

Calls (0)P/C Ratio: 10.00Puts (10K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tyra beats expectations, history suggests a potential stock increase of around +0.18%, confirming investor optimism.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of around +0.10%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any preliminary results.
2Management's commentary on strategies to improve financial performance and address EPS misses.
3Any insights into future product pipeline developments.
4Discussion on market conditions and competitive landscape in the biotechnology sector.
5Guidance on expected revenue growth or potential partnerships.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Tyra Biosciences, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors will closely analyze.

N/A

Revenue Growth

Although revenue estimates are not available, any growth in revenue would signal positive momentum for the company.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TYRA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.57%

Avg Stock Reaction

+0.14%

Last Quarter Recap

In Q1-2026, Tyra reported an EPS of -$0.64, missing estimates slightly. The stock reacted positively, gaining 3.79% the next day, indicating some investor optimism despite the loss.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Tyra can demonstrate significant progress in its clinical trials or report better-than-expected EPS, it could lead to a strong rally in the stock price.

Bear Case

Conversely, if the company fails to meet expectations again or provides disappointing updates on its therapies, it could lead to a further decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What updates can management provide on the progress of clinical trials?

Investors will be looking for any signs of success or setbacks in the trials, as these can greatly influence the stock's future performance.

How does management plan to address the recent EPS misses?

Understanding management's strategy to improve financial performance is crucial for investor confidence and stock stability.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Tyra's upcoming clinical trial results, which could be more favorable than anticipated.

Supporting Evidence

The options market is pricing a 9.39% move, suggesting significant expectations that may not align with historical performance.

Tyra's recent stock reactions indicate a potential for recovery if positive news emerges from clinical trials.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative significantly.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it could set the tone for Tyra's future growth and investor sentiment.

Bull Confirmed If

A significant improvement in clinical trial results or a surprise EPS beat could confirm the bull case.

Bear Confirmed If

Continued EPS misses or negative updates on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±9.39%

Historical Avg

±3.4%

Pricing rich

The options market is pricing in a significant move, indicating that investors are anticipating volatility around the earnings report.

Options are pricing ±9.4% while TYRA has averaged ±3.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

47.9%

Calls (0)P/C Ratio: 10.00Puts (10K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Tyra beats expectations, history suggests a potential stock increase of around +0.18%, confirming investor optimism.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of around +0.10%, reflecting ongoing investor concerns.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status of ongoing clinical trials and any preliminary results.
2Management's commentary on strategies to improve financial performance and address EPS misses.
3Any insights into future product pipeline developments.
4Discussion on market conditions and competitive landscape in the biotechnology sector.
5Guidance on expected revenue growth or potential partnerships.